Background New pharmacological targets are needed for restless legs syndrome. Preclinical
data suggest that a hypoadenosinergic state plays an important pathogenetic role. …

Objectives Recent animal models of restless legs syndrome (RLS) suggest that brain iron
deficiency is associated with a hypoadenosinergic state, with downregulation of adenosine A 1 …

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder
characterized by an urge to move the legs, usually accompanied by or felt to be caused …

Objectives To determine whether long-term treatment with dopaminergic agents (DAs)
might dampen the response to a non-dopaminergic agent, such as gabapentin enacarbil. …

Alemtuzumab is a humanized monoclonal antibody used to treat active relapsing-remitting
multiple sclerosis (RRMS) defined by clinical or imaging features. It is directed against …

Objective To analyze changes in substantia nigra (SN) iron deposits, assessed by quantitative
transcranial sonography (TCS), to obtain and compare substantia nigra echogenicity …

… Address correspondence to Dr Celia Garcia-Malo, Sleep Research Institute, Paseo de la
Habana 151, 28036 Madrid, Spain, [email protected]. RELATIONSHIP DISCLOSURE: Dr …

Two types of drugs have been extensively investigated for the treatment of restless legs
syndrome (RLS)/Willis-Ekbom disease (WED): dopamine agonists and α2δ ligands to the α2δ …

Obstructive sleep apnoea (OSA) and restless legs syndrome (RLS) are two of the most
prevalent sleep disorders and can coexist within the same patient. Nonetheless, the recognition …

Objective To evaluate the relation between systemic iron parameters (SIP) and substantia
nigra (SN) iron deposits, as assessed by transcranial sonography (TCS) in restless legs …